Antiretroviral agents - How best to protect infants from HIV and save their mothers from AIDS

New England Journal of Medicine

Volumn 351, Issue 3, 2004, Pages 289-292

  Coovadia, Hoosen ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG DOSE REGIMEN; EDITORIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL DISEASE; PERINATAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION; ANTIBIOTIC RESISTANCE; DEVELOPING COUNTRY; DISEASE TRANSMISSION; FEMALE; GENETICS; NEWBORN; NOTE; PREGNANCY; PREGNANCY COMPLICATION;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ZIDOVUDINE;

EID: 3142710188     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048128     Document Type: Editorial

References (16)

1. World Health Organization. Accelerating HIV prevention in the context of 3 by 5. (Accessed June 7, 2004, at http://www.who.int/ 3by5/publications/briefs/ hiv_prevention/en/.)
2. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351:217-28.
3. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to a nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-40.
4. Chalermchokcharoenkit A, Asavapiriyanont S, Teeraratkul A, et al. Combination short-course zidovudine plus 2-dose nevirapine for prevention of mother-to-child transmission: safety, tolerance, transmission, and resistance results. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:96. abstract.
5. Dabis F, Ekouévi DK, Rouet F, et al. Effectiveness of a short course zidovudine + lamivudine and peripartum nevirapine to prevent HIV-1 mother-to-child transmission: the ANRS 1201 ditrame-plus trial, Abidjan, Cote D'Ivoire. Presented at the Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13-16, 2003. abstract. (Accessed June 23, 2004, at http:// www.ias2003.org/admin/images/upload/195.pdf.)
6. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002;288:189-98.
7. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000;343:982-91.
8. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings: expert consultation, Geneva, 5-6 February 2004: a summary of the main points from the meeting. (Accessed June 23, 2004, at http://www.who.int/3by5/arv_pmtct/ en/.)
9. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-7.
10. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004;35:126-30.
11. Lyons F, Coughlan S, Byrne C, et al. Emergence of genotypic resistance in HIV-1-infected pregnant women taking HAART to reduce mother-to-child transmission of HIV-1. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004:892. abstract.
12. Cunningham CK, Chaix M-L, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group protocol 316. J Infect Dis 2002;186:181-8.
13. Fowler MG, Mofenson L, McConnell M. The interface of perinatal HIV prevention, antiretroviral drug resistance, and antiretroviral therapy: what do we really know? J Acquir Immune Defic Syndr 2003;34:308-11.
14. Servais J, Lambert C, Karita E, et al. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda. AIDS Res Hum Retroviruses 2004;20:279-83.
15. Giaquinto C. Genotypic resistance tests for the management of the HIV-infected pregnant patient in Africa. Scand J Infect Dis Suppl 2003;106:88-90.
16. AIDS epidemic update. Geneva: UNAIDS, December 2003. (Accessed June 23, 2004, at http://www.unaids.org.)